US loss of exclusivity · Neuroscience
Vraylar
AbbVie
2029
US generics from
2025
Today: 2026
2037
2025 worldwide sales
$3.6B
Date basis
Patent-expiry estimate
US generics
Approved, waiting to launch
Medicare price
−44% from 2027
Pharma Patent Cliff
by readouts.io
Data checked 8 October 2026 ·
Full Vraylar timeline →